Asia tech stocks slide tracking Wall St losses amid AI doubts, govt. uncertainty
On Friday, Scotiabank (TSX:BNS) initiated coverage on Avidity Biosciences (NASDAQ:RNA) with a Sector Outperform rating and set a price target of $70.00. The firm’s analyst Louise Chen highlighted the biotech company’s promising portfolio of therapies, which are currently in registrational studies and have the potential to become blockbusters in markets lacking approved drugs. According to InvestingPro data, analyst consensus remains strongly bullish with price targets ranging from $51 to $96, suggesting significant upside potential from the current trading price of $30.35.
Avidity Biosciences, which focuses on developing therapies for rare muscle disorders, has three key drugs in its pipeline: Del-desiran for myotonic dystrophy type 1 (DM1), Del-zota for Duchenne muscular dystrophy (DMD44), and Del-brax for facioscapulohumeral muscular dystrophy (FSHD). According to Chen, these therapies present an attractive investment opportunity as they approach potential regulatory approval. With a market capitalization of $3.65 billion and a strong financial position showing more cash than debt, the company appears well-positioned to advance its pipeline. InvestingPro analysis indicates the company maintains healthy liquidity with a current ratio of 15.73.
The analyst pointed out that while all three drugs are in registrational studies, there is a possibility for Del-zota and Del-brax to receive accelerated approval (AA). This prospect, coupled with the absence of other approved drugs for these conditions, positions Avidity Biosciences favorably in the market.
Chen’s analysis suggests that Avidity Biosciences’ stock is likely to experience an increase in value as the Food and Drug Administration (FDA) approvals for these therapies come into view. The anticipation of these regulatory milestones is expected to drive investor interest and positively impact the stock’s performance. While the stock has shown strong momentum with a 51.6% return over the past year, InvestingPro subscribers can access 8 additional key insights and a comprehensive Pro Research Report, providing deeper analysis of the company’s valuation and growth prospects.
In other recent news, Avidity Biosciences has been the focus of significant attention from analysts and investors. Cantor Fitzgerald reaffirmed its Overweight rating and set a price target of $96.00, expressing confidence in the company’s pipeline, which includes promising drugs for rare diseases like myotonic dystrophy and FSHD. The company’s strategic approach to clinical trials, such as the Phase 3 HARBOR trial for myotonic dystrophy, is expected to yield primary endpoint results by the first half of 2026. Additionally, Avidity plans to release full Phase 1/2 data from the MARINA trial soon, supporting the biological basis of their therapies.
H.C. Wainwright initiated coverage on Avidity with a Buy rating and a price target of $72.00, citing the successful establishment of its Antibody Oligonucleotide Conjugate platform and the execution of three clinical programs. The firm’s analyst highlighted the safety and sustained improvement shown in the myotonic dystrophy program through the MARINA studies. In the FSHD program, the drug Del-brax has shown potential for accelerated approval due to significant reductions in gene expression and improvements in clinical endpoints.
For the DMD program, Del-Zota has demonstrated favorable safety and efficacy, potentially meeting the criteria for accelerated approval for Exon 44 patients. Avidity Biosciences is also expanding into precision cardiology, aiming for future growth. The positive analyst outlooks reflect confidence in Avidity Biosciences’ potential for success in its various clinical programs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.